Nanomedicine is revolutionising cancer care. By harnessing particles smaller than 100 nanometers, scientists can now target cancer cells with precision while sparing healthy tissue. These nano-scale delivery vehicles—like liposomes and dendrimers—boast a high surface area and customizable chemistry, enabling smarter, safer therapies. 

Stellenbosch's plant-derived gold nanoparticles take this further: they are naturally synthesised, biocompatible, and selectively toxic to breast cancer cells. This next-generation formulation is reshaping what’s possible in precision oncology.

Preclinical tests have demonstrated the nanoparticles’ potent and selective anti-tumor activity against breast cancer cell lines, with minimal impact on healthy cells. The formulation has shown strong in vivo results in tumour suppression and survival benefits, positioning it as a promising candidate for further clinical development.